Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole

Table 2 Recurrence rate of erosive esophagitis: Intergroup differences and non-inferiority test

Endpoint	LPZ 15 mg		VPZ 10 mg	VPZ 20 mg
Week 24 (primary endpoint)1	16.8% (33/196)		5.1% (10/197)	2.0% (4/201)
Week 12 (secondary endpoint)1	12.2% (24/196)		2.5% (5/197)	1.0% (2/201)
Comparison	Difference and 95%CI (%)		Non-inferiority, P value	Fisher exact test, P value2
Week 24 (primary endpoint)
VPZ 10 mg vs LPZ 15 mg		-11.8 [-17.83, -5.69]	< 0.0001	0.0002
VPZ 20 mg vs LPZ 15 mg		-14.8 [-20.43, -9.26]	< 0.0001	< 0.0001
VPZ 10 mg vs VPZ 20 mg		-3.1 [-6.71, 0.54]	N/A	0.1090
Week 12 (secondary endpoint)
VPZ 10 mg vs LPZ 15 mg		-9.7 [-14.80, -4.62]	< 0.0001	N/A
VPZ 20 mg vs LPZ 15 mg		-11.2 [-16.04, -6.46]	< 0.0001	N/A
VPZ 10 mg vs VPZ 20 mg		-1.5 [-4.13, 1.05]	N/A	N/A

¹Values expressed as percentages with number of subjects in parentheses;

²Post hoc analysis. CI: Confidence interval; LPZ: Lansoprazole; VPZ: Vonoprazan; N/A: Not applicable.